ES2352547T3 - Método para tratar un trastorno vascular agudo. - Google Patents

Método para tratar un trastorno vascular agudo. Download PDF

Info

Publication number: ES2352547T3
Authority: ES; Spain
Prior art keywords: steroid; group; acute; mammal; use according
Prior art date: 2006-01-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES07709154T

Other languages

English (en)

Spanish (es)

Inventor

Herman Jan Thijmen Coelingh Bennink

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pantarhei Bioscience BV

Original Assignee

Pantarhei Bioscience BV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-01-09

Filing date

2007-01-09

Publication date

2011-02-21

2007-01-09 Application filed by Pantarhei Bioscience BV filed Critical Pantarhei Bioscience BV

2011-02-21 Application granted granted Critical

2011-02-21 Publication of ES2352547T3 publication Critical patent/ES2352547T3/es

Status Active legal-status Critical Current

2027-01-09 Anticipated expiration legal-status Critical

Links

238000000034 method Methods 0.000 title claims abstract description 47
230000001154 acute effect Effects 0.000 title claims abstract description 43
208000019553 vascular disease Diseases 0.000 title claims abstract description 26
206010059245 Angiopathy Diseases 0.000 title claims abstract description 15
150000003431 steroids Chemical class 0.000 claims abstract description 66
241000124008 Mammalia Species 0.000 claims abstract description 20
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 19
239000000126 substance Substances 0.000 claims abstract description 19
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 14
239000000203 mixture Substances 0.000 claims abstract description 11
239000002243 precursor Substances 0.000 claims abstract description 11
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 7
125000003545 alkoxy group Chemical group 0.000 claims abstract description 6
239000003814 drug Substances 0.000 claims description 41
229940079593 drug Drugs 0.000 claims description 40
206010002383 Angina Pectoris Diseases 0.000 claims description 32
208000024891 symptom Diseases 0.000 claims description 25
208000019695 Migraine disease Diseases 0.000 claims description 23
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 19
239000000006 Nitroglycerin Substances 0.000 claims description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
229960003711 glyceryl trinitrate Drugs 0.000 claims description 19
206010027599 migraine Diseases 0.000 claims description 19
BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 15
239000008194 pharmaceutical composition Substances 0.000 claims description 14
208000026106 cerebrovascular disease Diseases 0.000 claims description 13
230000002792 vascular Effects 0.000 claims description 13
239000003071 vasodilator agent Substances 0.000 claims description 13
208000024172 Cardiovascular disease Diseases 0.000 claims description 12
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims description 12
229940124549 vasodilator Drugs 0.000 claims description 12
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims description 11
208000035475 disorder Diseases 0.000 claims description 11
230000002093 peripheral effect Effects 0.000 claims description 10
239000000546 pharmaceutical excipient Substances 0.000 claims description 10
-1 sulfamic acid hydrocarbon Chemical class 0.000 claims description 10
229960003310 sildenafil Drugs 0.000 claims description 8
229960003708 sumatriptan Drugs 0.000 claims description 8
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 8
230000037396 body weight Effects 0.000 claims description 7
229960001789 papaverine Drugs 0.000 claims description 7
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 6
229960001476 pentoxifylline Drugs 0.000 claims description 6
BMUKKTUHUDJSNZ-UHFFFAOYSA-N 4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)COC1=CC=CC=C1 BMUKKTUHUDJSNZ-UHFFFAOYSA-N 0.000 claims description 5
229930008281 A03AD01 - Papaverine Natural products 0.000 claims description 5
ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 5
125000004429 atom Chemical group 0.000 claims description 5
229960002474 hydralazine Drugs 0.000 claims description 5
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 5
229960000201 isosorbide dinitrate Drugs 0.000 claims description 5
229960004819 isoxsuprine Drugs 0.000 claims description 5
229960003632 minoxidil Drugs 0.000 claims description 5
239000003521 serotonin 5-HT1 receptor agonist Substances 0.000 claims description 5
229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 4
YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
229960002460 nitroprusside Drugs 0.000 claims description 4
239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 4
239000004215 Carbon black (E152) Substances 0.000 claims description 3
229960002472 eletriptan Drugs 0.000 claims description 3
OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 claims description 3
229960002284 frovatriptan Drugs 0.000 claims description 3
SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 claims description 3
229930195733 hydrocarbon Natural products 0.000 claims description 3
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 claims description 3
229960003827 isosorbide mononitrate Drugs 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 claims description 2
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 2
KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 claims description 2
229960002133 almotriptan Drugs 0.000 claims description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
238000012377 drug delivery Methods 0.000 claims description 2
229960002479 isosorbide Drugs 0.000 claims description 2
229960005254 naratriptan Drugs 0.000 claims description 2
UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 claims description 2
XEZQLSOFXLPSJR-UHFFFAOYSA-N oxane-2-carbaldehyde Chemical compound O=CC1CCCCO1 XEZQLSOFXLPSJR-UHFFFAOYSA-N 0.000 claims description 2
229960000425 rizatriptan Drugs 0.000 claims description 2
TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 claims description 2
125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
229960001360 zolmitriptan Drugs 0.000 claims 1
UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 claims 1
AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 description 51
229950009589 estetrol Drugs 0.000 description 50
238000011282 treatment Methods 0.000 description 33
239000000262 estrogen Substances 0.000 description 17
229940011871 estrogen Drugs 0.000 description 16
239000000902 placebo Substances 0.000 description 16
229940068196 placebo Drugs 0.000 description 16
230000000694 effects Effects 0.000 description 15
239000006187 pill Substances 0.000 description 15
201000001881 impotence Diseases 0.000 description 14
206010019233 Headaches Diseases 0.000 description 13
208000002193 Pain Diseases 0.000 description 13
210000001367 artery Anatomy 0.000 description 13
208000010228 Erectile Dysfunction Diseases 0.000 description 12
230000036407 pain Effects 0.000 description 12
208000012322 Raynaud phenomenon Diseases 0.000 description 11
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
231100000869 headache Toxicity 0.000 description 11
229910052760 oxygen Inorganic materials 0.000 description 11
239000001301 oxygen Substances 0.000 description 11
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
206010008118 cerebral infarction Diseases 0.000 description 9
206010047139 Vasoconstriction Diseases 0.000 description 8
206010047163 Vasospasm Diseases 0.000 description 8
230000017531 blood circulation Effects 0.000 description 8
201000010099 disease Diseases 0.000 description 8
230000025033 vasoconstriction Effects 0.000 description 8
230000008901 benefit Effects 0.000 description 7
230000001965 increasing effect Effects 0.000 description 7
230000002107 myocardial effect Effects 0.000 description 7
239000007787 solid Substances 0.000 description 7
206010020772 Hypertension Diseases 0.000 description 6
208000003782 Raynaud disease Diseases 0.000 description 6
230000009471 action Effects 0.000 description 6
239000002775 capsule Substances 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
230000002526 effect on cardiovascular system Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
208000010125 myocardial infarction Diseases 0.000 description 6
230000024883 vasodilation Effects 0.000 description 6
201000001320 Atherosclerosis Diseases 0.000 description 5
201000006474 Brain Ischemia Diseases 0.000 description 5
206010008120 Cerebral ischaemia Diseases 0.000 description 5
206010008479 Chest Pain Diseases 0.000 description 5
210000004351 coronary vessel Anatomy 0.000 description 5
208000028867 ischemia Diseases 0.000 description 5
210000002414 leg Anatomy 0.000 description 5
239000000463 material Substances 0.000 description 5
208000031225 myocardial ischemia Diseases 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
206010028813 Nausea Diseases 0.000 description 4
208000018262 Peripheral vascular disease Diseases 0.000 description 4
208000006011 Stroke Diseases 0.000 description 4
206010043540 Thromboangiitis obliterans Diseases 0.000 description 4
230000000035 biogenic effect Effects 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
210000002683 foot Anatomy 0.000 description 4
230000006872 improvement Effects 0.000 description 4
208000001286 intracranial vasospasm Diseases 0.000 description 4
230000008693 nausea Effects 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
210000003899 penis Anatomy 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
239000000843 powder Substances 0.000 description 4
230000000391 smoking effect Effects 0.000 description 4
206010011703 Cyanosis Diseases 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010021143 Hypoxia Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
208000005392 Spasm Diseases 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
206010053648 Vascular occlusion Diseases 0.000 description 3
230000009102 absorption Effects 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000002411 adverse Effects 0.000 description 3
230000036770 blood supply Effects 0.000 description 3
230000002490 cerebral effect Effects 0.000 description 3
208000029078 coronary artery disease Diseases 0.000 description 3
230000002354 daily effect Effects 0.000 description 3
238000001647 drug administration Methods 0.000 description 3
102000015694 estrogen receptors Human genes 0.000 description 3
108010038795 estrogen receptors Proteins 0.000 description 3
230000002349 favourable effect Effects 0.000 description 3
230000006870 function Effects 0.000 description 3
210000002216 heart Anatomy 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000000583 progesterone congener Substances 0.000 description 3
238000011160 research Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
230000001568 sexual effect Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
229940032147 starch Drugs 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
210000003371 toe Anatomy 0.000 description 3
208000021331 vascular occlusion disease Diseases 0.000 description 3
239000002550 vasoactive agent Substances 0.000 description 3
YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 2
KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 2
201000000736 Amenorrhea Diseases 0.000 description 2
206010001928 Amenorrhoea Diseases 0.000 description 2
206010002388 Angina unstable Diseases 0.000 description 2
200000000007 Arterial disease Diseases 0.000 description 2
206010003175 Arterial spasm Diseases 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
206010061216 Infarction Diseases 0.000 description 2
206010027603 Migraine headaches Diseases 0.000 description 2
229910002651 NO3 Inorganic materials 0.000 description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
208000005764 Peripheral Arterial Disease Diseases 0.000 description 2
208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 2
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
206010034960 Photophobia Diseases 0.000 description 2
229930182558 Sterol Natural products 0.000 description 2
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
206010043647 Thrombotic Stroke Diseases 0.000 description 2
208000007814 Unstable Angina Diseases 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
230000004075 alteration Effects 0.000 description 2
231100000540 amenorrhea Toxicity 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
238000002583 angiography Methods 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
230000037007 arousal Effects 0.000 description 2
230000003143 atherosclerotic effect Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000002612 cardiopulmonary effect Effects 0.000 description 2
229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000006735 deficit Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
230000010339 dilation Effects 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
229940000406 drug candidate Drugs 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
230000001856 erectile effect Effects 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
230000001146 hypoxic effect Effects 0.000 description 2
230000007574 infarction Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
201000004332 intermediate coronary syndrome Diseases 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
230000036651 mood Effects 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
210000004165 myocardium Anatomy 0.000 description 2
230000007971 neurological deficit Effects 0.000 description 2
239000002547 new drug Substances 0.000 description 2
229940126701 oral medication Drugs 0.000 description 2
208000035824 paresthesia Diseases 0.000 description 2
229960003418 phenoxybenzamine Drugs 0.000 description 2
229960001999 phentolamine Drugs 0.000 description 2
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000000757 progestagenic effect Effects 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
230000035807 sensation Effects 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
230000036299 sexual function Effects 0.000 description 2
229960002639 sildenafil citrate Drugs 0.000 description 2
DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 2
ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
150000003432 sterols Chemical class 0.000 description 2
235000003702 sterols Nutrition 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 2
238000002562 urinalysis Methods 0.000 description 2
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
UCTWMZQNUQWSLP-SECBINFHSA-N (S)-adrenaline Chemical compound CNC[C@@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-SECBINFHSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 1
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
108010058207 Anistreplase Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
206010002942 Apathy Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
102400000967 Bradykinin Human genes 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
208000033386 Buerger disease Diseases 0.000 description 1
206010006784 Burning sensation Diseases 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
239000002083 C09CA01 - Losartan Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
206010008469 Chest discomfort Diseases 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
208000032928 Dyslipidaemia Diseases 0.000 description 1
206010014522 Embolism venous Diseases 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241001539473 Euphoria Species 0.000 description 1
206010015535 Euphoric mood Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010019851 Hepatotoxicity Diseases 0.000 description 1
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
ALOBUEHUHMBRLE-UHFFFAOYSA-N Ibutilide Chemical compound CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ALOBUEHUHMBRLE-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010022562 Intermittent claudication Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
208000017170 Lipid metabolism disease Diseases 0.000 description 1
108010007859 Lisinopril Proteins 0.000 description 1
206010027304 Menopausal symptoms Diseases 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
206010029333 Neurosis Diseases 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
206010052143 Ocular discomfort Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241001282135 Poromitra oscitans Species 0.000 description 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
201000001068 Prinzmetal angina Diseases 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
206010040007 Sense of oppression Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
208000007718 Stable Angina Diseases 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
201000004810 Vascular dementia Diseases 0.000 description 1
206010048215 Xanthomatosis Diseases 0.000 description 1
206010048232 Yawning Diseases 0.000 description 1
YWXYYJSYQOXTPL-JGWLITMVSA-N [(3r,3ar,6s,6as)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-JGWLITMVSA-N 0.000 description 1
229960000446 abciximab Drugs 0.000 description 1
230000007495 abnormal renal function Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
239000000464 adrenergic agent Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229940092229 aldactone Drugs 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
230000002009 allergenic effect Effects 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
229960003318 alteplase Drugs 0.000 description 1
229960005260 amiodarone Drugs 0.000 description 1
IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
229960000528 amlodipine Drugs 0.000 description 1
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000009165 androgen replacement therapy Methods 0.000 description 1
229960000983 anistreplase Drugs 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
229940124572 antihypotensive agent Drugs 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
229940127218 antiplatelet drug Drugs 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
208000021328 arterial occlusion Diseases 0.000 description 1
210000002565 arteriole Anatomy 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
210000001217 buttock Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
229960004195 carvedilol Drugs 0.000 description 1
NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000001627 cerebral artery Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960002155 chlorothiazide Drugs 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000009194 climbing Effects 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000037020 contractile activity Effects 0.000 description 1
210000005226 corpus cavernosum Anatomy 0.000 description 1
230000002498 deadly effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
229960002069 diamorphine Drugs 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
229960002768 dipyridamole Drugs 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
229960001066 disopyramide Drugs 0.000 description 1
UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
229960001089 dobutamine Drugs 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000008451 emotion Effects 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000009986 erectile function Effects 0.000 description 1
OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
229960004943 ergotamine Drugs 0.000 description 1
XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
229960003580 felodipine Drugs 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
210000003811 finger Anatomy 0.000 description 1
229960000449 flecainide Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000002778 food additive Substances 0.000 description 1
235000013373 food additive Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
210000004247 hand Anatomy 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000007686 hepatotoxicity Effects 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000001624 hip Anatomy 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
208000021822 hypotensive Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
208000018875 hypoxemia Diseases 0.000 description 1
229960004053 ibutilide Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229960002056 indoramin Drugs 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
208000021156 intermittent vascular claudication Diseases 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229960004130 itraconazole Drugs 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
238000009533 lab test Methods 0.000 description 1
229960001632 labetalol Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
229960002394 lisinopril Drugs 0.000 description 1
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
230000003908 liver function Effects 0.000 description 1
244000144972 livestock Species 0.000 description 1
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
229960004773 losartan Drugs 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
229940127215 low-molecular weight heparin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000009245 menopause Effects 0.000 description 1
230000004630 mental health Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
229960001186 methysergide Drugs 0.000 description 1
229960002237 metoprolol Drugs 0.000 description 1
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
208000015238 neurotic disease Diseases 0.000 description 1
229960000715 nimodipine Drugs 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
231100000862 numbness Toxicity 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
230000036284 oxygen consumption Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
229960002965 pravastatin Drugs 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
229960000244 procainamide Drugs 0.000 description 1
REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
230000010349 pulsation Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000004648 relaxation of smooth muscle Effects 0.000 description 1
210000002254 renal artery Anatomy 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000000333 selective estrogen receptor modulator Substances 0.000 description 1
229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000000952 serotonin receptor agonist Substances 0.000 description 1
229960002855 simvastatin Drugs 0.000 description 1
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
229960002370 sotalol Drugs 0.000 description 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
201000005671 spondyloarthropathy Diseases 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
230000002966 stenotic effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000004885 tandem mass spectrometry Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
208000004043 venous thromboembolism Diseases 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
229960005080 warfarin Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

ES07709154T 2006-01-09 2007-01-09 Método para tratar un trastorno vascular agudo. Active ES2352547T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US757027P		2006-01-09
EP06100159		2006-01-09
EP06100159		2006-01-09

Publications (1)

Publication Number	Publication Date
ES2352547T3 true ES2352547T3 (es)	2011-02-21

Family

ID=36100928

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES07709154T Active ES2352547T3 (es)	2006-01-09	2007-01-09	Método para tratar un trastorno vascular agudo.

Country Status (4)

Country	Link
CN (1)	CN101378762A (de)
AT (1)	ATE481973T1 (de)
DE (1)	DE602007009358D1 (de)
ES (1)	ES2352547T3 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT3701944T (lt)	2015-06-18	2022-04-11	Estetra Srl	Burnoje disperguojamas dozavimo vienetas, kurio sudėtyje yra estetrolio komponentas
ES2671160T3 (es) *	2015-06-18	2018-06-05	Mithra Pharmaceuticals S.A.	Unidad de dosificación orodispersable que contiene un componente estetrol
KR102712911B1 (ko)	2016-08-05	2024-10-04	에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼	월경통 및 생리통의 관리방법
TWI801561B (zh)	2018-04-19	2023-05-11	比利時商依思特拉私人有限責任公司	化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh)	2020-04-16	2025-08-11	比利時商埃斯特拉有限責任公司	具有降低之副作用之避孕組成物

2007
- 2007-01-09 CN CNA2007800045937A patent/CN101378762A/zh active Pending
- 2007-01-09 ES ES07709154T patent/ES2352547T3/es active Active
- 2007-01-09 AT AT07709154T patent/ATE481973T1/de not_active IP Right Cessation
- 2007-01-09 DE DE602007009358T patent/DE602007009358D1/de active Active

Also Published As

Publication number	Publication date
CN101378762A (zh)	2009-03-04
DE602007009358D1 (de)	2010-11-04
ATE481973T1 (de)	2010-10-15

Publication	Publication Date	Title
CA2636638C (en)	2014-02-18	A method of treating an acute vascular disorder
JP3469901B2 (ja)	2003-11-25	ヒトの性的応答を調節するための方法及び製剤
EP0714300B1 (de)	1998-12-23	Verfahren zur regulierung der sexuellen reaktion beim menschen
Vogt et al.	1997	Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction
JP2009280621A (ja)	2009-12-03	ヒトの性応答を調節するための組み合わせ治療
ES2352547T3 (es)	2011-02-21	Método para tratar un trastorno vascular agudo.
Sorbera et al.	2001	IC-351
Ekmekçioğlu et al.	2005	Effects of sildenafil citrate on ejaculation latency, detumescence time, and refractory period: placebo-controlled, double-blind, crossover laboratory setting study
ES2329815T3 (es)	2009-12-01	S-mirtazapina para el tratamiento de sofocos.
US4687771A (en)	1987-08-18	Method for treatment of male impotence
Yap et al.	2002	Topical agents and erectile dysfunction: is there a place?
RU2421211C2 (ru)	2011-06-20	Средство коррекции мужских сексуальных дисфункций
Marais	2015	The pharmacological management of erectile dysfunction
CN104619323B (zh)	2018-03-09	用于在治疗性功能障碍中使用的a3腺苷受体配体
Chouaib et al.	2021	Priapism and cannabism: A case report and review of the literature
WO2017100324A1 (en)	2017-06-15	Combination therapy for treating female hypoactive sexual desire disorders
US20030207891A1 (en)	2003-11-06	Combination therapy for modulating the human sexual response
Turner	1996	Factor VIII. Blood clotting factor that is deficient in haemophilia and Von Willebrand's disease. Used intravenously to stop episodes of uncontrollable bleeding. Factor IX concentrate. HIV-free clotting
AU4203600A (en)	2000-10-23	Methods for modulating the human sexual response
HK1209342B (en)	2018-09-07	A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
HK1028197B (en)	2007-04-13	Combination therapy for modulating the human sexual response